statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Latest Ratings for XNCR
 DateFirmActionFromTo Feb 2022HC Wainwright & Co.MaintainsBuy Feb 2022BMO CapitalInitiates Coverage OnOutperform Dec 2021HC Wainwright & Co.Initiates Coverage OnBuy
 View...

Analyst Scoreboard: 6 Ratings For Xencor

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart...

Xencor Appoints Bart Cornelissen as Chief Financial Officer

In trading on Friday, shares of Xencor, Inc (XNCR) crossed below their 200 day moving average of 21.32, changing hands as low as 20.93 per share. Xencor, Inc shares are currently trading...

XNCR Crosses Below Key Moving Average Level

This indicator may be signaling that XNCR's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Xencor (XNCR, $21.96) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024

This price move could indicate a change in the trend, and may be a buy signal for investors...

Xencor (XNCR, $22.43) price moved above its 50-day Moving Average on March 27, 2024

This is a signal that XNCR's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

Xencor (XNCR, $21.53) Stochastic Oscillator left the oversold zone on March 26, 2024

Xencor, Inc. (NASDAQ:XNCR  Get Free Report) CEO Bassil I. Dahiyat sold 12,528 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $23.43...

Xencor, Inc. (NASDAQ:XNCR) CEO Bassil I. Dahiyat Sells 12,528 Shares of Stock

Xencor (XNCR, $22.03) entered Downtrend as Momentum indicator drops below 0 level on Mar 14, 2024

Xencor, Inc. (NASDAQ:XNCR  Get Free Report) CEO Bassil I. Dahiyat sold 2,741 shares of the companys stock in a transaction dated Monday, March 11th. The shares were sold at an average...

Bassil I. Dahiyat Sells 2,741 Shares of Xencor, Inc. (NASDAQ:XNCR) Stock

Xencor (NASDAQ:XNCR  Get Free Report) was upgraded by stock analysts at StockNews.com from a sell rating to a hold rating in a note issued to investors on...

Xencor (NASDAQ:XNCR) Stock Rating Upgraded by StockNews.com

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Volume	1.48M
52-Wk High	$28.96
52-Wk Low	$16.49

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.83	--	--	N/A
Q4'23	-$0.11	-$0.31	-192.36%	MISSED
Q3'23	-$0.73	-$0.40	44.93%	BEAT
Q2'23	-$0.80	-$0.37	53.58%	BEAT
Q1'23	-$0.66	-$1.02	-53.83%	MISSED

XNCR Xencor Inc

About

Feed

News

Sentiment

Earnings

Fundamentals